Articles from PharmaEssentia Corporation

PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical company headquartered in Taiwan with deep expertise in the development of novel biologics for hematology and oncology, and its U.S. subsidiary PharmaEssentia USA Corporation today announced that the global corporate Board of Directors has approved an investment of approximately US$46 million to establish a new, wholly owned manufacturing subsidiary in Puerto Rico. The planned investment supports the company’s global manufacturing expansion strategy and is intended to serve as a future manufacturing center for the U.S. market and long-term global demand for BESREMi® (ropeginterferon alfa-2b).

Please replace the release dated January 6, 2025, with the following corrected version due to multiple revisions.

PharmaEssentia Corporation (TWSE: 6446), a global commercial biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference Thursday, January 16, 2025 at 1:45 pm. PST.

PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the appointment of Joseph R. Horvat as Global Chief Commercial Officer.

PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced a slate of nine new abstracts exploring the use of ropeginterferon alfa-2b-njft, known in market as BESREMi®, will be presented during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA.

PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that it has entered into an exclusive licensing agreement with FORUS Therapeutics Inc (“FORUS”) for the registration and distribution of BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of polycythemia vera (PV), in Canada.

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the appointment of Beth A. Krewson as Head of Legal.

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the promotion of Robert B. Geller, M.D. to General Manager. Dr. Geller joined the Company as Head of Medical earlier this year. In his new role as General Manager, Dr. Geller will bring his medical expertise to the team and continue to focus on serving more patients with myeloproliferative neoplasms (MPN).

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology, oncology and immunology, today announced completion of enrollment for two clinical trials evaluating its ropeginterferon alfa-2b-njft (BESREMi®).

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced the publication of an original article in the British Journal of Clinical Pharmacology, “Exposure–efficacy and exposure–safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.” Overall, these analyses indicate that patients with polycythemia vera (PV) treated with ropeginterferon alfa-2b (marketed as BESREMi®) had an increased probability of achieving complete hematologic response (CHR) and a molecular response with acceptable safety risks when using a 250–350–500 µg dosing regimen. Writing and editorial support were funded by PharmaEssentia, however authors retained full editorial control and provided final approval on all content.

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) have recently been updated to include ropeginterferon alfa-2b-njft, marketed as BESREMi®, as a preferred first-line cytoreductive therapy option for the treatment of adults with symptomatic, low-risk polycythemia vera (PV). Ropeginterferon alfa-2b-njft is the only preferred therapeutic option for both high-risk and low-risk (symptomatic) PV regardless of treatment history.1

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology, oncology and immunology, announced the publication of a manuscript reviewing the clinical safety, efficacy and practical management of treatment with two pegylated interferons – peginterferon alfa-2a and ropeginterferon alfa-2b-njft (marketed as BESREMi®). The manuscript, "Interferons in the Treatment of Myeloproliferative Neoplasms” was co-authored by 12 renowned myeloproliferative neoplasm (MPN) specialists and published in Therapeutic Advances in Hematology. Writing and editorial support were funded by PharmaEssentia, however authors retained full editorial control and provided final approval on all content.

PharmaEssentia Corporation, (TPEx:6446), a global biopharmaceutical innovator headquartered in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced it has entered into a license agreement with WuXi Biologics Ireland Limited to obtain the global exclusive rights to research, develop, manufacture and commercialize a myeloid immune checkpoint antibody candidate. PharmaEssentia will take over responsibility for the subsequent preclinical and clinical development efforts.

PharmaEssentia Corporation, (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the company is included in the FTSE Global Equity Index Series, FTSE All-World Index, FTSE global All-Cap and total-Cap Indices, and the FTSE Global Mid Cap Index. These inclusions became effective after close of business on Friday, September 15, 2023.

PharmaEssentia Corporation (TPEx:6446), a leading fully integrated biopharmaceutical company in Taiwan, today announced the publication of new results from a Phase 2 clinical study with ropeginterferon alfa-2b (marketed as BESREMi®) for the treatment of patients with polycythemia vera (PV). This study, which was conducted in China, demonstrated the efficacy and tolerability of ropeginterferon alfa-2b using an alternate dosing regimen that has a higher starting dose and a more rapid dose titration as compared to current U.S. label dosing. The publication, titled “A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera,” was published in Experimental Hematology & Oncology and co-authored by PharmaEssentia researchers.

PharmaEssentia Corporation (TPEx:6446), a leading fully integrated biopharmaceutical company in Taiwan, today announced that it has entered into an exclusive license agreement with Pint-Pharma GmbH for the registration and promotion of BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of polycythemia vera (PV), a rare blood cancer, in Brazil, Argentina, Colombia, Chile, Peru, Ecuador, and Mexico.

PharmaEssentia Corporation (TPEx:6446, LuxSE: PHECA, PHECR), a leading fully integrated biopharmaceutical company in Taiwan, today announced the closing of its Global Depositary Receipt (GDR) offering of 34,000,000 shares of common stock at US$13.61 per share, generating US$462.7 million.

PharmaEssentia Corporation, (TPEx:6446), a global biopharmaceutical innovator headquartered in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced plans for a new PharmaEssentia Innovation Research Center (PIRC) in the greater Boston, Massachusetts area. The facility is expected to recruit 25 scientists over the next two years.

PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023.

PharmaEssentia USA Corporation (PEC USA), a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced that it will host an Investor Day on Wednesday, November 30, 2022, 8:00 - 10:30 a.m. ET, at Convene (101 Park Avenue) in New York City.

PharmaEssentia USA Corporation (PEC USA), a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced the recent appointment of three new female executives to the company’s U.S. leadership team.

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the clinical rationale and protocol for the SURPASS-ET trial evaluating ropeginterferon alfa-2b-njft as a second-line treatment option for adults with high-risk essential thrombocythemia (ET) has been published in the journal, Future Oncology.

PharmaEssentia Corporation, (TPEx:6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced the appointment of Lih-Ling Lin, PhD, as Chief Scientific Officer as of August 1st. In this newly formed role, Dr. Lin will lead the company’s global research and development (R&D) activities to expand and diversify the pipeline and to enhance the company’s R&D engagement globally and in critical markets, including the United States.

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that it will receive a 2022 Industry Innovation Award from the National Organization for Rare Disorders (NORD®) for the introduction of BESREMi® (ropeginterferon alfa-2b-njft) as a treatment for polycythemia vera (PV), a rare blood cancer. PharmaEssentia will accept the award at the 2022 Rare Impact Awards ceremony in Cleveland, OH on June 26, 2022.

PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced a series of data presentations will illustrate outcomes with ropeginterferon alfa-2b (marketed as BESREMi®) among adults with polycythemia vera (PV) during the European Hematology Association’s Hybrid Congress (EHA2022), June 9-17 in Vienna, Austria.

PharmaEssentia Corporation (TPEx: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the U.S. Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of adults with polycythemia vera (PV).

PharmaEssentia Corporation (TPEx: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced plans to present new updates on its pipeline during the 63rd American Society of Hematology Annual Meeting, December 11-14, 2021.

PharmaEssentia USA Corporation, a subsidiary of Taiwan-based PharmaEssentia Corp. (TPEx: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), seeking approval for ropeginterferon alfa-2b-njft for the treatment of polycythemia vera (PV), a rare blood cancer.

PharmaEssentia Corporation (TPEx: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, has announced the appointment of Dr. Norio Komatsu, a renowned expert in myeloproliferative neoplasms (MPNs) research in Japan, as Chairperson and Executive Director of the Company’s Japanese subsidiary.